Market Place
Sourcing Support
Cogent Biosciences Presents Positive Phase 3 Trial Results
21 Apr 2026 //
FIRSTWORD PHARMA
Cogent Bio Presents Posters At AACR Annual Meeting 2026
19 Apr 2026 //
FIRSTWORD PHARMA
Cogent Submits NDA for Bezuclastinib in GIST
01 Apr 2026 //
GLOBENEWSWIRE
FDA Accepts Cogent`s Bezuclastinib NDA for Non-AdvSM Mastocytosis
16 Mar 2026 //
GLOBENEWSWIRE
Cogent Biosciences to Highlight Bezuclastinib Posters at AAAAI
28 Feb 2026 //
GLOBENEWSWIRE
Cogent Biosciences Reports 2025 Results and Business Highlights
17 Feb 2026 //
GLOBENEWSWIRE
Cogent’s Bezuclastinib Combo Gains FDA Breakthrough Status
26 Jan 2026 //
GLOBENEWSWIRE
Cogent Biosciences Files NDA for Bezuclastinib Under RTOR Review
20 Jan 2026 //
GLOBENEWSWIRE
Cogent Biosciences Files NDA for Bezuclastinib Under RTOR
20 Jan 2026 //
GLOBENEWSWIRE
Cogent Biosciences Outlines 2026 Bezuclastinib Milestones
12 Jan 2026 //
GLOBENEWSWIRE
Cogent Biosciences to Present at 44th J.P. Morgan Conference
06 Jan 2026 //
GLOBENEWSWIRE
Cogent Submits NDA for Bezuclastinib in NonAdvanced Mastocytosis
30 Dec 2025 //
GLOBENEWSWIRE
Cogent Biosciences Reports Bezuclastinib Success In Advsm Trial
08 Dec 2025 //
GLOBENEWSWIRE
Cogent Biosciences Unveils Complete Bezuclastinib SUMMIT Data
06 Dec 2025 //
GLOBENEWSWIRE
Cogent Bio Joins Jefferies Global Healthcare Conference
14 Nov 2025 //
GLOBENEWSWIRE
Cogent Eyes FDA Approval After Clearing Another Ph. 3 Hurdle
12 Nov 2025 //
FIERCE BIOTECH
Cogent Biosciences Announces 2031 Convertible Senior Notes
10 Nov 2025 //
GLOBENEWSWIRE
Cogent Biosciences Presents at ASH Meeting
03 Nov 2025 //
GLOBENEWSWIRE
Cogent Biosciences Presents KRAS Poster At Confernece
24 Oct 2025 //
GLOBENEWSWIRE
Cogent Biosciences Reveals FDA Breakthrough For Bezuclastinib
20 Oct 2025 //
GLOBENEWSWIRE
Cogent Bio Reports Inducement Grants Per Nasdaq Lr 5635(c)(4)
29 Sep 2025 //
GLOBENEWSWIRE
Cogent Biosciences to Participate in Citi Biopharma Conference
26 Aug 2025 //
GLOBENEWSWIRE
Cogent Biosciences Reports Q2 2025 Financial Results
05 Aug 2025 //
GLOBENEWSWIRE
Cogent Closes Upsized Offering With Full Overallotment
10 Jul 2025 //
GLOBENEWSWIRE
Cogent Biosciences Proposes $150M Public Common Stock Offering
08 Jul 2025 //
GLOBENEWSWIRE
Cogent Biosciences Prices Upsized Public Stock Offering
08 Jul 2025 //
GLOBENEWSWIRE
Cogent’s Bezuclastinib Hits All Endpoints in SUMMIT Trial
08 Jul 2025 //
GLOBENEWSWIRE
Cogent Hits Primary Endpoint, Building Case for Blueprint Rival
07 Jul 2025 //
FIERCE BIOTECH
Cogent Biosciences Secures $400M Non-Dilutive Financing
11 Jun 2025 //
GLOBENEWSWIRE
Cogent Biosciences Joins Jefferies Global Healthcare Conference
29 May 2025 //
GLOBENEWSWIRE
Cogent Biosciences Reports First Quarter 2025 Financial Results
06 May 2025 //
GLOBENEWSWIRE
Cogent Biosciences Presents Posters at AACR Meeting 2025
25 Apr 2025 //
GLOBENEWSWIRE
Cogent Biosciences to Present Posters at 2025 AACR Meeting
25 Mar 2025 //
GLOBENEWSWIRE
Cogent Biosciences to Attend Leerink Healthcare Conference
07 Mar 2025 //
GLOBENEWSWIRE
Cogent Bio`s Trial Shows Symptom Improvement In Systemic Mastocytosis
27 Feb 2025 //
GLOBENEWSWIRE
Cogent Biosciences Reports Q4 & FY 2024 Results & Highlights
25 Feb 2025 //
GLOBENEWSWIRE
Cogent To Present Bezuclastinib Poster In NonAdvSM At AAAAI
10 Feb 2025 //
GLOBENEWSWIRE
Cogent Bioscience to Participate in Guggenheim Biotech Conference
30 Jan 2025 //
GLOBENEWSWIRE
Cogent Previews 2025 Goals For Bezuclastinib & Targeted Drugs
13 Jan 2025 //
GLOBENEWSWIRE
Cogent Bio`s Presentation at 43rd Annual J.P. Morgan Conference
08 Jan 2025 //
GLOBENEWSWIRE
Cogent Bio Announces Summit Trial Result for Systemic Mastocytosis
09 Dec 2024 //
GLOBENEWSWIRE
Cogent Bio Reports Business Highlights & Q3 2024 Financial Results
12 Nov 2024 //
GLOBENEWSWIRE
Cogent Biosciences Presents Bezuclastinib Data at ASH 2024
05 Nov 2024 //
GLOBENEWSWIRE
Cogent Biosciences Expands Pipeline into KRAS
23 Oct 2024 //
GLOBENEWSWIRE
Cogent Biosciences Completes Phase 3 PEAK Trial Enrollment for GIST
03 Sep 2024 //
GLOBENEWSWIRE
